China’s Hua Medicine plans $400m Hong Kong IPO, led by Goldman – sources

HONG KONG, March 9 (Reuters) – Chinese drug developer Hua Medicine is planning to raise at least $400 million in an initial public offer in Hong Kong in the latest in a series of biotech floats in the city, said people with knowledge of the matter.
( read original story …)


Related Post

No separate sections on Hong Kong for new history ...
views 8
A new curriculum framework for teaching Chinese hi...
Chinese smartphone giant Xiaomi’s Hong Kong ...
views 12
Xiaomi, the world’s fourth-largest smartphone make...
Hong Kong shares down amid N.Korea, trade tensions
views 12
The top gainers among H-shares were CSPC Pharmaceu...
What Next for BOC HONG KONG HOLDINGS LTD. ORDINARY...
views 12
The stock of BOC HONG KONG HOLDINGS LTD. ORDINARY ...
Why Fook Lam Moon is still Hong Kong’s ‘tyco...
views 15
For more than half a century, Hong Kong has been a...
Flight Review: Hong Kong Airlines’ Impressive A350...
views 15
Hong Kong is a dazzling city. With a dazzling inte...
Hong Kong Dollar Jumps Most in a Month on Corporat...
views 14
The Hong Kong dollar rallied the most in a month a...
Bus driver unionists warn of escalating action as ...
views 16
Bus driver unions in Hong Kong say they would “not...
Greater Bay Area leader calls on Guangdong provinc...
views 14
Han’s trip – his first since he took up the vice-p...
A Payments Battle Is Brewing in Hong Kong
views 23
Alipay’s azure blue logos began appearing two year...